Market Research Report
Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2016
|Published by||Global Markets Direct||Product code||410982|
|Published||Content info||59 Pages
|Middle East Respiratory Syndrome (MERS) - Pipeline Review, H2 2016|
|Published: December 30, 2016||Content info: 59 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome - Pipeline Review, H2 2016, provides an overview of the Middle East Respiratory Syndrome (Infectious Disease) pipeline landscape.
Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Middle East Respiratory Syndrome (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Middle East Respiratory Syndrome (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.